EXOZ invizyne.com: Forward Price-to-Revenue Multiple
Margins at eXoZymes Inc (EXOZ) are declining due to energy shocks and sanctions. The projected P/S ratio visualizes this volatility, where describes the current status of the metric. Rising petrochemical prices and logistics disruptions are weighing on production. High laboratory costs, coupled with a lack of scale, are creating a significant financial burden on the young biotech company.
EXOZ (Invizyne): analytical breakdowns and indicator data
- current price and projected stock value:
- company stock capitalization data:
- business book valuation details:
- company total debt and liquidity indicators:
- business earnings and investment ratios data:
EXOZ - Final Profit|Projected Future Earnings eXoZymes Inc|EXOZ - Business Payback Period|Future Price to Earnings Invizyne Technologies, Inc.|EXOZ - Growth-Adjusted P/E Ratio|EV/EBITDA Multiple Invizyne|EXOZ - Operating profit before deduction of amortization|Net earnings per share (EPS TTM) eXoZymes|EXOZ - Net earnings per one share for the last twelve months|Year-over-year net earnings per share growth for the last 12 months invizyne.com|EXOZ - Earnings per share growth this year|Net earnings per share growth forecast for next year eXoZymes Inc
- revenue and sales details:
Analysis of all company metrics:eXoZymes EXOZ
Stable cash flow and the fulfillment of obligations by eXoZymes Inc (EXOZ) create a solid foundation for assessing the market premium for future growth. The forward price-to-sales ratio measures investor expectations regarding sales expansion rates, while the forward P/S trend helps determine whether the asset is overvalued relative to its actual business scaling potential.
Competitor analysis
Forward P/S Multiple HLN (Haleon)|Kenvue Inc (KVUE) - Market Cap to Future Revenue Ratio|VRNA: Forward Price-to-Revenue Multiple|MENS (Jyong Bio) - Market Cap to Projected Revenue|Ligand Pharmaceuticals (LGND) - Price-to-Projected Revenue Ratio|Market Cap to Future Revenue Ratio amneal.com (AMRX)|Forward Price-to-Revenue Multiple PRGO|Alvotech S.A. - Future Price to Revenue|Forward Price-to-Revenue Multiple LQDA (Liquidia Technologies)|GLPG - Market Cap to Future Revenue Ratio|Price-to-Projected Revenue Ratio ANI Pharmaceuticals ANIP|MNKD - Forward Price-to-Revenue Multiple|Amphastar Pharmaceuticals, Inc. - Forward P/S Multiple|Market Cap to Future Revenue Ratio Pacira Pharmaceuticals|ARS Pharma (SPRY) - Price-to-Projected Revenue Ratio|TBPH - Market Cap to Expected Sales Ratio|Forward Price-to-Revenue Multiple AQST|SCPH: Forward Price to Sales|Forward P/S Multiple TECX|Market Cap to Expected Sales Ratio Tonix Pharma|Price-to-Projected Revenue Ratio China SXT Pharmaceuticals, Inc. SXTC|EPRX: Market Cap to Projected Revenue|BioHarvest Sciences - Forward P/S Multiple|Oramed Pharmaceuticals (ORMP) - Forward Price-to-Revenue Multiple|ENTX: Forward P/S Multiple|Market Cap to Future Revenue Ratio MindWalk Holdings, Inc. (HYFT)|Forward Price-to-Revenue Multiple ABVC|Market Cap to Projected Revenue CPIX (Cumberland Corp)|Price-to-Projected Revenue Ratio Quantum BioPharma Ltd (QNTM)|FGEN - Market Cap to Future Revenue Ratio|Telomir Pharmaceuticals, Inc. - Forward Price-to-Revenue Multiple|RANI (Rani Therapeutics Holdings) - Future Price to Revenue|SNYR - Price-to-Projected Revenue Ratio|Future Price to Revenue RLYB|LEXX: Forward P/S Multiple|pulmatrix.com - Forward Price to Sales|PTHL (Pheton Holdings Limited) - Forward P/S Multiple|Forward P/S Multiple Aptorum|Price-to-Projected Revenue Ratio Lyra Therapeutics, Inc (LYRA)|IBO (Impact BioMedical, Inc.) - Forward Price to Sales|Price-to-Projected Revenue Ratio TNF Pharmaceuticals, Inc. TNFA|YCBD - Forward Price-to-Revenue Multiple|PainReform - Forward P/S Multiple|CYTO - Forward P/S Multiple|LIPO (Lipella) - Forward Price-to-Revenue Multiple|OptiNose Corp - Forward Price to Sales|Price-to-Projected Revenue Ratio Pieris Pharmaceuticals|Market Cap to Future Revenue Ratio procapsgroup.com PROC|Forward Price-to-Revenue Multiple PTPI (Petros Pharmaceuticals, Inc.)|Price to Expected Revenue Ratio QLI|Forward P/S Multiple SLRN (ACELYRIN, Inc.)|Forward Price to Sales TFFP
